Multiple Ascending Dose Study of BMS-754807 in Patients With Solid Tumors in Japan
The purpose of this clinical study is to establish the maximum tolerated dose of BMS-754807 when administered orally on a once daily schedule in subjects with solid tumors.
Neoplasms
DRUG: BMS-754807
To determine the Maximum Tolerated Dose of BMS-754807 based on the Dose Limited Toxicity which observed during the first 28 days, Within the first 28 days
To assess the safety and tolerability, Day 1, 8, 15, 22, 29, thereafter every 2 weeks|To establish recommended Phase 2 dose of BMS-754807 when administered orally on a once daily schedule, Day 1, 8, 15, 22, 29, thereafter every 2 weeks|To assess the metabolic effect on blood glucose, Day 1, 8, 15, 22, 29, thereafter every 2 weeks|To assess the pharmacokinetics of BMS-754807 administered orally on a once daily schedule, Day 1, 8, 15, 22, 29, thereafter every 2 weeks|To assess any preliminary evidence of anti-tumor activity, Day 1, 8, 15, 22, 29, thereafter every 2 weeks|To explore potential biomarkers of biological response, Day 1, 8, 15, 22, 29, thereafter every 2 weeks
The purpose of this clinical study is to establish the maximum tolerated dose of BMS-754807 when administered orally on a once daily schedule in subjects with solid tumors.